Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and with three or more circulating tumoral cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer

NCT03641976

Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy Unresectable Metastatic Right-sided Colon Cancer, Stage IV

UNKNOWN PHASE2

Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)

NCT01640444

Colorectal Cancer Metastatic

COMPLETED PHASE2

Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer

NCT01321957

Metastatic Colorectal Cancer

COMPLETED PHASE2

A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC

NCT02246049

Colorectal Neoplasms

COMPLETED PHASE2

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

NCT00354978

Colorectal Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

modified FOLFOX6 + bevacizumab

Group Type ACTIVE_COMPARATOR

modified FOLFOX6 + bevacizumab

Intervention Type DRUG

* Bevacizumab 5 mg/kg iv, day 1, followed by
* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by
* 5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:

* LV 400 mg/m2 iv administered over a period of 2 hours, followed by
* 5-FU 400 mg/m2 iv bolus, followed by
* 5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).

Experimental

FOLFOXIRI+bevacizumab

Group Type EXPERIMENTAL

FOLFOXIRI + Bevacizumab

Intervention Type DRUG

* Bevacizumab 5 mg/kg iv, followed by
* Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by
* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by
* LV 400 mg/m2 iv administered over a period of 2 hours, followed by
* 5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

modified FOLFOX6 + bevacizumab

* Bevacizumab 5 mg/kg iv, day 1, followed by
* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by
* 5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:

* LV 400 mg/m2 iv administered over a period of 2 hours, followed by
* 5-FU 400 mg/m2 iv bolus, followed by
* 5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).

Intervention Type DRUG

FOLFOXIRI + Bevacizumab

* Bevacizumab 5 mg/kg iv, followed by
* Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by
* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by
* LV 400 mg/m2 iv administered over a period of 2 hours, followed by
* 5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient's Informed consent in written.
2. Age between 18 and 70 years old.
3. Eastern Cooperative Oncology group performance status (ECOG) 0-1.
4. Life expectancy of at least 3 months.
5. Histological confirmation of adenocarcinoma of the colon or rectum.
6. To be included in the study patients should present \> or equal 3 CTC in peripheral blood.
7. Measurable metastatic stage IV disease with at least 1 measurable metastatic lesion following Response Evaluation Criteria In Solid Tumors (RECIST) criteria v 1.1 (non suitable for radical surgery at the inclusion time).
8. Prior radiotherapy is allowed but must be completed at least 4 weeks before randomization (if applicable).
9. Adequate bone marrow, liver and renal function.
10. Women of childbearing potential must have a negative serum or urine pregnancy test. Postmenopausal women must have been amenorrheic for at least 12 months.Both men and women participating in this study must use adequate contraception.
11. Subject must have the ability, in the opinion of the investigator, to comply with all the study procedures and follow-up examinations.

Exclusion Criteria

1. Previous chemotherapy for metastatic disease.
2. Prior treatment with Bevacizumab, or Epidermal Growth Factor Reception (EGFR) inhibitors
3. Any anticancer treatment (chemotherapy, hormonal treatment, radiation treatment, surgery , immunotherapy, biologic therapy or tumour embolization) within 4 weeks before randomization.
4. Use of any investigational drug within 4 weeks before start the treatment
5. Clinical or radiographic evidence of brain metastasis.
6. Uncontrolled hypertension (systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg on repeated measurement) despite optimal medical management.
7. Previous history of hypertensive encephalopathy or hypertensive crises.
8. Current or history of peripheral neuropathy \> or equal to 1 National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE).
9. Patients classified as fragile according to criteria listed in the protocol.
10. Significant cardiovascular disease (e.g. cerebrovascular accident (CVA), myocardial infarction, within 6 months before randomization). Unstable angina, congestive heart failure New York Heart Association (NYHA) ≥ class II, arrhythmia that requires treatment within 3 months before randomization.
11. Significant vascular disease (e.g. aortic aneurism requiring surgical intervention, pulmonary embolic, peripheral arterial thrombosis) within 6 months before randomization.
12. Previous history of significant haemorrhage /severe, within 1 month before randomization.
13. Major surgery, open surgical biopsy or significant traumatic injury within 4 weeks before randomization.
14. Large bore needle biopsy of a major organ within 14 days before randomization. Placement of central venous access port \> or equal to 7 days before randomization is permitted
15. Evidence or history of bleeding diathesis or coagulopathy.
16. International Normalized Ratio (INR) \> 1.5 within 14 days prior to starting study treatment. EXEMPTION: patients on full anticoagulation must have an in-range INR \[usually between 2-3\]. Any anticoagulation therapy must be at stable dosing prior to enrollment.
17. History of previous abdominal fistula or gastrointestinal perforation within 6 months before randomization.
18. Serious non-healing wound, ulcer or bone fracture.
19. Acute or sub-acute of intestinal occlusion or history of intestinal inflammatory disease.
20. History of uncontrolled convulsive crises.
21. History of pulmonary fibrosis, acute lung disease or interstitial pneumonia.
22. Chronic, actual o recent use (10 days prior first drug administration) of acetylsalicylic acic (aspirin) \> 325 mg/day or clopidogrel (75mg/day) or other treatments that can cause gastrointestinal ulcer (low-dose aspirin is permitted \< or equal to 325 mg/day).
23. Urinary protein excretion \> or equal to 2+ (dipstick). If \> or equal 2 g proteinuria is detected with dipstick, a 24-hour period urine test will be performed and the result should be \< or equal to 1 g/24 hours to permit the inclusion of the patient in the clinical trial.
24. Known human immunodeficiency virus infection or chronic hepatitis B or C infection or other uncontrolled, severe concurrent infection .
25. Current infection \> or equal to Grade 2 (NCI-CTCAE).
26. Any previous or concurrent cancer different to colorectal carcinoma within 5 years before to start the treatment. Subjects with successfully treated, non-invasive cancers, including cervical cancer in situ, basal cell carcinoma will be allowed to participate in the clinical trial. Or those cancer treated with curative intention without disease evidence in the last 5 years at least.
27. Known or suspected allergy or hypersensitivity to any component of Bevacizumab, oxaliplatin, irinotecan, or 5-FU/LV.
28. Any medical, psychological, or social condition that may interfere with the subject's participation in the study or evaluation of the study results.
29. Any psychological, familial or geographic situation that interferes in the adequate follow.up and adherence to the study protocol.
30. Women who are pregnant or breast-feeding.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No